$HUMA News

Benchmark Maintains Speculative Buy on Humacyte, Raises Price Target to $2

HC Wainwright & Co. Reiterates Buy on Humacyte, Maintains $3 Price Target

Humacyte Says Symvess Is Now Under Contract With Strategic Acquisition Center Of US Department Of Veterans Affairs

TD Cowen Maintains Buy on Humacyte, Raises Price Target to $1.5

BTIG Maintains Buy on Humacyte, Lowers Price Target to $2

Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript

Humacyte Q1 EPS $(0.09) Beats $(0.11) Estimate, Sales $495.000K Miss $1.455M Estimate

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement Revision

Fresenius Medical Care’s Symvess Deal Shift And What It Means For Valuation

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

BTIG Reiterates Buy on Humacyte, Maintains $3 Price Target

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte To Host KOL Event On April 28 To Discuss Unmet Need And Current Treatment Landscape For Hemodialysis Patients With End-Stage Renal Disease

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®